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Purpose: Radiotherapy-induced radiation retinopathy can develop in over 40% of eyes treated for uveal melanoma.
Triamcinolone acetonide (TA) and anecortave acetate (AA) can be used to treat radiation retinopathy. It is not known
whether TA or AA has any effect on potentially still viable uveal melanoma cells in the choroid after radiotherapy. We
therefore studied the effect of these drugs on the proliferation of uveal melanoma cell lines in vitro. Furthermore, as these
drugs are supposed to counteract vascular leakage, we determined their effect on the expression and production of the
proangiogenic vascular endothelial growth factor-A (VEGF-A), the antiangiogenic pigment epithelium-derived factor
(PEDF), and thrombospondin-1 (TSP-1) in uveal melanoma cells.
Methods: Three uveal melanoma cell lines were treated in vitro with TA or AA. Cell proliferation was measured by
counting cells and using the Water-Soluble Tetrazolium Salt-1 (WST-1) assay. VEGF-A and PEDF production was
measured by ELISA, and intracellular expression of angiogenic-associated genes including VEGF-A, PEDF, and TSP-1
was determined by real-time quantitative RT–PCR.
Results: We found no effect of TA or AA on tumor cell growth or production of VEGF-A and PEDF in any of the three
uveal melanoma cell lines tested. Regarding expression as measured by RT–PCR, TA had an inhibiting effect on TSP-1
in only one cell line, and no effect on VEGF-A or PEDF. AA showed a similar lack of effect.
Conclusions: Since TA and AA do not stimulate uveal melanoma cell growth, it seems to be safe to use these drugs to
treat radiation retinopathy after irradiation for uveal melanoma. Additional experiments using more cell lines or primary
tumor cell cultures are needed to validate this conclusion. Furthermore, the results of our study suggest that TA does not
exert its antileakage effect through downregulation of VEGF-A or upregulation of TSP-1 or PEDF in uveal melanoma
cell lines. It is possible that TA and AA influence these pro- and antiangiogenic factors only under hypoxic circumstances.
Further investigation is needed.
Uveal  melanoma  (UM)  is  the  most  common  primary
intraocular  tumor  in  adults,  with  an  incidence  of
approximately 5–7 per 1,000,000 in Caucasian populations
[1-4]. The five-year tumor-related survival rate is about 70%–
80% [5,6], and eventually about 50% of patients will die from
the disease [7,8]. Because the eye lacks lymphatic vessels, the
route of dissemination is almost exclusively hematogenous.
The most common site of metastasis formation is the liver
[9,10]. Predictors of survival for UM patients are identified
by histologic cell type, tumor diameter, tumor location, age,
gender [11], and cytogenetic parameters. Loss of chromosome
3 is one of the most significant predictors for UM-related
deaths [12,13]. There are different modes of therapy available
for treating a primary UM. Enucleation remains a common
treatment for large tumors. Small and medium-sized tumors
with a prominence <8 mm can be treated with proton beam
therapy, local resection, or radiation [14,15]. Radiotherapy is
often  combined  with  transpupillary  thermotherapy,  which
may  also  allow  treatment  of  larger  tumors  [16,17].
Radiotherapy, however, not only damages UM cells, but also
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normal  healthy  cells  located  in  the  immediate  area
surrounding  the  tumor.  Capillary  endothelial  cells  are
especially sensitive to radiation and presumably die directly
or later by mitotic death [18]. Capillary endothelial cell loss
causes changes in the structure and permeability of the vessels
in  the  affected  area.  This  leads  to  an  occlusive
microangiopathy, clinically known as radiation retinopathy.
A variety of sight-threatening manifestations are associated
with  radiation  retinopathy,  such  as  macular  edema  and
neovascularization [19]. The onset of radiation retinopathy
occurs on average 26 months after radioactive plaque therapy
[20].  The  cause  of  this  delay  is  not  quite  clear,  although
duration of the endothelial cell cycle and delayed mitotic cell
death might be an explanation [18]. Gunduz et al. [21] found
that  approximately  5%  of  patients  treated  by  radioactive
plaque developed radiation retinopathy after one year. After
five years this percentage rose to about 40%.
At the moment, there is no established effective treatment
for radiation retinopathy and its complications, although laser
photocoagulation  has  shown  some  beneficial  effect  [20].
Finger and Chin [22] demonstrated that antiangiogenic agents,
such as Avastin, have a beneficial effect.
Triamcinolone acetonide (TA) is a glucocorticoid that has
already been shown to improve vision for a few months in
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1752patients  with  macular  edema  associated  with  diabetic
retinopathy [23-25] and in patients with exudative age-related
macular  degeneration  (ARMD)  [26].  Although  the  causal
mechanisms  underlying  these  diseases  differ,  diabetic
retinopathy,  exudative  ARMD,  and  radiation  retinopathy
share  the  same  sight-threatening  complications,  such  as
macular  edema  and  neovascularization.  A  recent  study
reported  a  temporary  positive  effect  of  intravitreal  TA
injections in a group of 31 patients with radiation maculopathy
[27].
While TA may be a suitable drug to treat complications
of radiation retinopathy, its effect on UM cells is unknown.
The possibility that there are living UM cells in the choroid
of eyes treated with radiotherapy cannot be excluded [28];
local recurrences do develop [29]. We therefore set out to
study the effect of TA on the proliferation of UM cells before
using this drug in patients with radiation retinopathy. To our
knowledge, this has not been investigated previously.
TA has been shown to have an antiangiogenic effect
[30-32], though the mechanism by which this effect comes
about  is  not  clear.  The  extent  of  tumor  angiogenesis  is
determined  by  the  balance  between  proangiogenic  and
antiangiogenic molecules, released by both tumor cells and
surrounding cells [33]. The formation of new vessels is a
process involving endothelial cells; tumor cells that lack a
sufficient  blood  supply  are  most  likely  the  incentive  of
angiogenesis. Vascular endothelial growth factor-A (VEGF-
A)  plays  an  important  role  in  angiogenesis,  regulating
vasopermeability  and  the  proliferation  and  migration  of
endothelial cells [34]. VEGF-A seems also to be the key
mediator  in  ocular  vessel  diseases  as  well  as  in  tumor
angiogenesis [35].
We also studied two inhibitors of angiogenesis, pigment
epithelium-derived  factor  (PEDF)  and  thrombospondin-1
(TSP-1). Various studies have documented that PEDF inhibits
angiogenesis in the eye [36,37], whereas TSP-1 has been
shown  to  inhibit  cutaneous  melanoma  progression  by
suppressing tumor vessel formation [38].
One of the disadvantages of TA, however, is that it causes
ocular hypertension in about 30% of the cases [39] and may
lead  to  glaucomatous  damage.  A  new  steroid-derived
substance, anecortave acetate (AA), an angiostatic cortisone,
has been developed to be devoid of corticosteroid side effects
such as ocular hypertension [40]. Hence, AA may be a good
alternative  to  TA.  A  first  study  of  AA  administered  in  a
juxtascleral  depot  to  treat  subfoveal  choroidal
neovascularization  in  ARMD  showed  good  results  in  the
prevention of further vessel development [41]. We therefore
analyzed the effect of both TA as well as AA on proliferation,
expression and production of pro- and antiangiogenic factors.
METHODS
Cell lines: Three well described cell lines were selected on the
basis  of  known  differences  in  VEGF-A  production  (low,
medium, high) to perform our experiments: Mel 285, 92–1
and OCM-1. Cell line OCM-1 was kindly provided by Dr. J.
Kan-Mitchell (Karmanos Cancer Institute, Detroit, MI) [43].
Cell line 92–1 was established in our laboratory [42]. Mel 285
was  a  generous  gift  of  Dr.  B.R.  Ksander  (Schepens  Eye
Research Institute, Boston, MA) [44]. Cell lines Mel 285 and
92–1  were  cultured  in  Roswell  Park  Memorial  Institute
(RPMI)  1640  (Gibco  Life  Technologies,  Breda,  the
Netherlands) to which 10% fetal calf serum, 2% glutamine
(Gibco), and 2% penicillin and streptomycin (Gibco) were
added. OCM-1 was cultured in Dulbecco's Modified Eagle's
Medium (DMEM; Gibco) with 10% fetal calf serum and 2%
penicillin and streptomycin (Gibco). Cultures were passaged
every three to four days.
Triamcinolone  acetonide  and  AL-4940  preparations:  We
used  triamcinolone  acetonide  T6501  (Sigma-Aldrich,  St.
Louis, MO). The recommended intravitreal dose of TA is 4 mg
(0.1 ml) [27]. The dose to which the UM cells are expected to
be  exposed  in  vivo  after  injection  of  TA  is  1  mg/ml.
Unfortunately,  due  to  massive  TA  crystal  deposits  the
maximal tolerated dose in vitro was 0.04 mg/ml. Ten mg TA
was suspended in 230 μl methanol, producing a 100 mM stock
suspension. This stock was serially diluted with medium to
concentrations of 10 μM and 100 μM. Extra methanol was
added to the 10 μM suspension to obtain a concentration of
0.1%  methanol,  similar  to  the  100  μM  suspension.  As  a
control, we used solutions of 0.1% methanol in medium. We
used  9(11)-dehydrocortisol  (AL-4940–06;  Alcon
Laboratories, Fort Worth, TX) instead of AA. In vivo AA is
rapidly deacetylated into AL-4940, and AL-4940 is therefore
the predominantly present active form [45]. A 10 mM stock
solution was prepared by dissolving 5.4 mg AL-4940 in 1.6 ml
dimethyl sulfoxide (DMSO). This stock was serially diluted
with medium to concentrations of 0.1, 1.0, and 10 μM. A
solution of 0.1% DMSO was used as control.
Triamcinolone  acetonide  administration:  Growth  assays
were performed in triplicate. For each assay, 64 wells per cell
line were filled with 1x104 UM cells per well in 1 ml medium,
using 24 well plates. Cells were allowed to settle for 24 h.
After 24 h, the regular medium was replaced by 1 ml of one
of  the  following  media:  RPMI/DMEM  (control),  RPMI/
DMEM  with  methanol  (second  control),  10  μM  TA
suspension, or 100 μM TA suspension; for the AL-4940 assay:
RPMI (control), RPMI with DMSO (second control), 0.1 μM
AL-4940  solution,  1.0  μM  AL-4940  solution,  or  10  μM
AL-4940 solution. Cells were cultured in an incubator at 37 °C
and 5.0% CO2.
Cell proliferation and cytotoxicity: Four, six, eight, and ten
days  after  medium  replacement,  cells  were  counted  or
replaced with fresh specific media. Cells from four wells of
each cell line at one time point were pooled to collect a high
enough number of cells to obtain a reliable count. Cell death
was determined by trypan blue dye-exclusion using a Bürker
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1753counting chamber (Omnilabo, Breda, the Netherlands). In
addition, cell proliferation was measured by mitochondrial
function  using  the  WST-1  assay  (Roche  Diagnostics,
Indianapolis, IN), as previously described [46]. In short, 96
well plates were allotted 1250 UM cells per well and either
filled  with  regular  medium  (control)  or  100  μM  TA
suspension. Absorbance was measured at 450 nm (n=8) on a
multiwell spectrophotometer (Perkin Elmer, Wellesley, MA).
VEGF-A and PEDF production: In the supernatant obtained
on  day  eight,  VEGF-A  and  PEDF  concentrations  were
determined using commercial solid phase sandwich enzyme-
linked immunosorbent assay kits. For VEGF-A, we used a
human  VEGF-A  ELISA  immunoassay  kit  (Biosource,
Camarillo, CA), and for PEDF, we used a PEDF Sandwich
ELISA antigen detection kit (BioProducts MD, Middletown,
MD).
Real-time Quantitative RT–PCR analysis: Several different
gene  mRNA  expressions  were  analyzed  by  real-time
quantitative reverse transcriptase–polymerase chain reaction
(RT–PCR). RNA was isolated on day 8 in one TA assay, using
an Rneasy® Mini Kit (Qiagen, Valencia, CA). RNA samples
were  stored  at  −80  °C  until  further  processing,  when
approximately  1  μg  of  RNA  per  sample  was  reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad,
Hercules, CA). The solutions (20 μl) were diluted by adding
sterile water until the volume reached a total of 100 μl. In 96
wells, 2 μl of this solution was added to a 15 μl solution of iQ
SYBR Green Supermix, forward and reverse primers (10 μM
solutions) for VEGF-A, PEDF, TSP-1, beta-actin (β-ACTIN),
hypoxantine  phosphoribosyltransferase  (HRPT),  or
ribosomal protein S11 (RPS-11), and sterile water (volume
ratio respectively 10:1:1:8). The primers for all genes under
study were designed with the Primer Express software (PE
Applied  Biosystems;  Foster  city,  CA;  Table  1)  [47].  A
quantitative analysis of the samples was then performed for
all genes by real-time quantitative RT–PCR in a MyiQ iCycler
real-time  PCR  system  (Bio-Rad).  An  accepted  method  to
correct  the  sample-to-sample  variation  when  determining
gene expression is to select a cellular housekeeping gene that
serves as an endogenous control, against which the target gene
expression  levels  can  be  normalized  [48].  RPS-11  is  a
housekeeping gene that has been recently used to normalize
gene expression in UM cells [47]. β-actin is a relatively stable
cytoskeletal  protein  generally  thought  to  be  present  at  a
constant level in cells, regardless of experimental treatment
or  technical  procedure  [49].  HPRT,  an  enzyme  in  purine
metabolism,  is  reported  as  a  constitutively  expressed
housekeeping gene [49,50].
The PCR reaction settings were 95 °C for 3 min, then 40
cycles at 95 °C for 30 s and 60 °C for 30 s, then 95 °C for 1
min and 60 °C for 1 min. Using a control, we calculated
assigned relative quantity for any sample for all genes as
follows:
Relative Quantitysample (Gene X)=EGene X
[C
T
 (Control) – C
T
 (sample)]
where E represents efficiency of primer or (probe) set,
CT (Control) equals the average CT for the sample which has been
assigned as a control, and CT (sample) is the average CT for the
sample. This is referred to as normalized expression [51].
Statistical analysis: Data are expressed as the mean±standard
deviation.  Student’s  t-test  was  used  to  determine  whether
there  were  statistically  significant  differences  between
treatment groups in the cell viability assay. A p<0.05 was
considered statistically significant.
RESULTS
Influence of TA and AA on UM cell proliferation: TA and AA
may be potential drugs to treat radiation retinopathy. However
harmful side effects such as proliferation of UM cells have to
be ruled out.
Treatment of UM cells with TA did not induce cell death
as  measured  by  the  Bürker  counting  chamber  (data  not
shown). The WST-1 assay demonstrated no significant effect
of TA treatment on cell proliferation of the UM cell lines 92.1
(p=0.755), OCM-1 (p=0.844), and Mel285 (p=0.487; Figure
1). AA showed similar results. TA and AA had no toxic effect
on UM cells, as there were no differences in the percentages
of  dead  cells  between  the  different  treatments  (data  not
shown).
TABLE 1. PRIMER SEQUENCES OF THE GENES STUDIED IN THE RT–PCR ASSAY
Primer Gene Forward primer (5’-3’) Reverse primer (5’-3’)
Endogenous controls RPS-11 AAGCAGCCGACCATCTTTCA CGGGAGCTTCTCCTTGCC
  HRPT CGAGATGTGATGAAGGAGATGG GCAGGTCAGCAAAGAATTTATAGC
  β-ACTIN CGGGACCTGACTGACTACCTC CTCCTTAATGTCACGCACGATTT
Genes under study VEGF-A GCCCTTGCCTTGCTGCTCTACC GTGATGATTCTGCCTCCTCCTTC
  PEDF AGCATTCTCCTTCTCGGTGTGG CCTCACGGTCCTCTCTTCATCC
  TSP-1 AGGTCTTCAGCGTGGTGTCC ACAAACAGGGTGATGCTCTTCC
Primer sequences of the control and studied genes that were used in real-time quantitative RT-PCR assay to determine level of
expression  in UM cell lines. Abbreviations: β-ACTIN is beta-actin; HPRT is hypoxantine phosphoribosyltransferase; RPS-11
is ribosomal protein S11.
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1754VEGF-A and PEDF production: To investigate any direct
pro- or antiangiogenic effects of TA and AA on UM cells, we
studied the influence of these drugs on VEGF-A and PEDF
production of three UM cell lines using an ELISA on culture
supernatant. Since cell numbers per well differed considerably
between some treatments and experiments, we corrected for
the number of cells by dividing the concentration of VEGF-
A or PEDF measured in the supernatant by the amount of cells
present in the same well. All cell lines produced VEGF-A and
Figure 1. Effect of TA on uveal melanoma cell proliferation. Cells
were  treated  with  four  different  suspensions:  Park  Memorial
Institute/Dulbecco’s  Modified  Eagle  Medium  (RPMI/DMEM;
control), RPMI/DMEM with methanol (second control), 10 mM TA
suspension,  or  100  mM  TA  suspension.  Cell  proliferation  was
determined by a WST-1 assay (absorbance (OD) and the mean±SD
is provided for each time point (n=8)). No substantial difference was
seen  in  proliferation  of  uveal  melanoma  cell  lines  between  TA
treatment and control (cell line 92.1 (p=0.755), OCM-1 (p=0.844),
and Mel285 (p=0.487)). Abbreviations: OD is optical density; TA is
triamcinolone acetonide; CO is control.
PEDF, but clear differences were observed in the amounts:
OCM-1 produced the highest levels of VEGF-A (50 pg/ml/
104  cells);  92–1  produced  approximately  one-fifth  of  this
amount (10 pg/ml/104 cells); and Mel 285 produced the lowest
amount of VEGF-A (5 pg/ml/104 cells).
Cell line 92–1 produced large amounts of PEDF (2.000
pg/ml/104 cells), around 100 times the amount produced by
cell line OCM-1 (20 pg/ml/104 cells). Mel 285 produced very
little PEDF (3 pg/ml/104 cells). Addition of TA or AA to the
cell  cultures  had  no  effect  on  either  VEGF-A  or  PEDF
production (Figure 2A,B).
VEGF-A, PEDF, and TSP-1 expression: We determined by
real-time quantitative RT–PCR whether TA or AA had any
effect on several genes in UM cell lines that were associated
with angiogenesis. VEGF-A was expressed in all cell lines at
variable levels. TA treatment had no major (>1.0 time fold
difference) effect on VEGF-A expression. On the contrary,
TA gave a dose-dependent reduction of TSP-1 expression in
Mel285 (time fold difference=1.5–2.9). TSP-1 was hardly
expressed in 92.1 (Figure 3). AA had no significant effect
either   on   VEGF-A  or   TSP-1   expression.   PEDF  is
highly  expressed  in  cell   line  92–1   and  only   to  a
minimal extend in the other cell lines. PEDF expression in cell
line 92–1 was not affected by TA or AA (data not shown).
DISCUSSION
Our  results  showed  no  apparent  stimulating  or  inhibiting
effect of TA on UM cell proliferation in the concentrations
used in this study [27]. The effect of TA on UM cell lines has
not yet been investigated, but the effect of TA on other cell
types has been the object of some studies. For instance, TA
was found to inhibit the growth of retinal pigment epithelium
(RPE) when ARPE 19 cells were treated with concentrations
ranging from 1 μM to 2.3 mM, but stimulated growth at a
concentration of 1 nM [52,53]. Another study, using bovine
retinal endothelial cells, found that TA at a concentration of
115 μM had no effect on growth; concentrations ranging from
230 μM to 4.6 mM had an inhibiting effect, and concentrations
of 6.8 mM and higher were cytotoxic [54]. Likewise, in vitro
incubation of RPE with corticosteroids induced a specific and
dose-dependent reduction of cell viability. These toxic events
were not associated with the anti-inflammatory activity of
these compounds but depended on the hydrosolubility of their
formulation [55].
While previous studies on RPE cells demonstrated an
inhibition of VEGF production and expression by TA, we
found no effect of TA on VEGF-A production or expression
in UM cells. For instance, TA reduced VEGF expression of
ARPE19 cells under oxidative stress [53] and inhibited cobalt-
stimulated VEGF production in Müller cells, probably by a
destabilization of VEGF mRNA [56]. The lack of inhibition
of TA on VEGF-A production and expression in our study
could perhaps be explained by the absence of specific stimuli
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1755that would upregulate VEGF-A production and expression,
such as oxidative stress or cobalt administration. In the study
by Sears et al. [56], only cobalt-stimulated VEGF production
was inhibited by TA, while basal VEGF production was not
affected. Similarly, another study showed no alteration in
VEGF expression by TA in a rat retina when no special stress
was applied [57].We are currently performing experiments to
determine the effect of TA and other drugs on UM cells under
stressful conditions, such as hypoxia.
Figure 2. Production of VEGF-A and PEDF in three different UM
cell lines exposed to various TA and AA doses. Cells were treated
with  four  or  five  different  suspensions.  A:  For  triamcinolone
acetonide (TA) experiments, we used either Park Memorial Institute/
Dulbecco’s  Modified  Eagle  Medium  (RPMI/DMEM;  control),
RPMI/DMEM  with  methanol  (second  control),  a  10  mM  TA
suspension, or a 100 mM TA suspension ; B: For anecortave acetate
(AA)  experiments,  we  used  either  RPMI  (control),  RPMI  with
dimethyl  sulfoxide  (DMSO;  second  control),  0.1  mM  AL-4940
solution, 1.0 mM AL-4940 solution, or 10 mM AL-4940 solution.
The level of vascular endothelial growth factor-A (VEGF-A) protein
(n=2) is shown in pg/ml (mean±SD). All cell lines produced VEGF-
A  and  pigment  epithelium-derived  factor  (PEDF),  but  clear
differences were observed: OCM-1 produced the highest levels of
VEGF-A, while cell line Mel 285 produced the lowest amount of
VEGF-A. Cell line 92–1 produced large amounts of PEDF (>2000
pg/ml). Mel 285 produced scant PEDF. Addition of TA or AA to the
cell cultures had no effect on either VEGF-A or PEDF production.
PEDF  inhibits  angiogenesis  by  inducing  apoptosis  in
endothelial cells that try to form new vessels [58,59]. Besides
the  separate  levels  of  VEGF-A  and  PEDF,  the  balance
between  the  two  seems  to  be  decisive  in  whether  or  not
angiogenesis  takes  place  [60].  Yang  et  al.  previously
demonstrated  expression  of  PEDF  in  UM  cell  lines.
Furthermore, they observed an inhibitory effect of angiostatin
on  the  ratio  of  VEGF:PEDF  mRNA  levels  in  vitro  [59].
Likewise, Mel 285, 92–1, and OCM-1 all produced PEDF in
our  experiments.  We  observed  no  effect  of  TA  on  the
production of PEDF by any of the UM cell lines. Therefore,
stimulation of production of PEDF by UM cells seems not to
be the antiangiogenic working mechanism of this drug under
normal circumstances. The high expression of PEDF by cell
line 92–1 was unexpected, since PEDF has been shown to
work  as  a  tumor  growth  inhibitor  through  antiangiogenic
mechanisms [61-63] and cell line 92–1 was derived from a
highly malignant tumor [42]. However, there are reports that
melanocytic  tumors  have  a  relatively  high  expression  of
PEDF  [64].  Also,  PEDF  might  have  a  biphasic  activity,
inhibiting angiogenesis at normal amounts, but stimulating
angiogenesis at high concentrations [65].
The balance between VEGF-A and PEDF, as we have
described, seems also to be influenced by TSP-1 in that it
inhibits endothelial cell migration and proliferation and also
induces apoptosis [66]. In cell line Mel 285, TSP-1 expression
was about twofold inhibited in cells grown in TA compared
to the control cells. Previous reports on the effect of TA on
the expression of TSP-1 could not be found, though some
effects  of  other  corticosteroids  have  been  reported.
Figure 3. The effect of TA (two doses) on gene expression of VEGF-
A and TSP-1 in three different uveal melanoma cell lines. Cells were
treated with four different suspensions: Park Memorial Institute/
Dulbecco’s  Modified  Eagle  Medium  (RPMI/DMEM;  control),
RPMI/DMEM  with  methanol  (second  control),  10  mM
triamcinolone  acetonide  (TA)  suspension,  or  100  mM  TA
suspension. Expression levels of vascular endothelial growth factor-
A (VEGF-A) and thrombospondin-1 (TSP-1) are normalized against
two endogenous controls (normalized fold; mean±SD). Experiments
were performed twice. VEGF-A was expressed in all cell lines at
variable levels. TA treatment had no major (>1.0 fold) effect on
VEGF-A expression. TSP-1 was not expressed in 92.1. Mel 285
showed a decreased TSP-1 expression (time-fold difference=1.5–
2.9) after treatment with TA.
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1756Hydrocortisone upregulated TSP-1 expression in a glioma cell
line [67], and dexamethasone increased TSP-1 expression in
a murine trofoblast-like cell culture [68]. The results of Mel
285 do not agree with this, and may indicate an unexpected
effect of TA. TSP-1 expression of cell line 92–1 was very low,
possibly due to inactivation of this gene in the same manner
as described for hypermethylated p16 (INK4a) [69].
Parallel experiments with AA, designed to eliminate any
possible side effects of the glucocorticoid fraction, showed
similar results as with TA. There seems to be no differential
effect  of  this  angiostatic  cortisone  compared  to  TA  on
potentially  still  viable  UM  cells  in  the  choroid  after
radiotherapy; both drugs have hardly any effect at all.
The risk of an increase in local recurrences of UM by TA
or AA in the treatment of radiation retinopathy by direct
stimulation of UM cells seems to be low. We based these
conclusions  on  a  restricted  number  of  cell  lines,  and
extrapolation to the in vivo situation is by definition limited.
In addition, the clinical dose of TA could not be investigated
due to massive crystal deposits. Perhaps a certain threshold
has to be reached before TA can demonstrate any effect.
Nonetheless, our results suggest that TA does not exert any
antiangiogenic  effect  through  influencing  basal  VEGF-A,
PEDF, TSP-1 production or expression in UM cells. However,
influence of hypoxia and stimulation of these cell lines by
VEGF or FGF2 or by antiangiogenic factors is possible and
is under investigation.
Furthermore,  there  are  many  other  pro-  and
antiangiogenic  factors  that  could  be  altered  by  TA.
Plasminogen activator inhibitor type-1 for instance, has been
implicated  in  metastasis  formation  and  tumor-associated
angiogenesis  in  UM  [70],  and  would  be  an  interesting
candidate for further studies. These factors will need further
investigation.
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